NEW YORK CITY, NY / ACCESS Newswire / October 30, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of EyePoint, Inc. ("EyePoint" or "the Company") (NASDAQ:EYPT). Investors who purchased EyePoint securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/eyepoint-inc-eypt-investigation.

EyePoint Investigation Details

On August 17, 2026, EyePoint issued a press release "announcing topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYUT (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD)." The press release disclosed that change from baseline in best corrected visual acuity versus 2 mg aflibercept (Regeneron Pharmaceuticals' (REGN) Eylea) was not met in the entire dataset. On this news, EyePoint's stock price fell $9.88 per share, or 66.98%, to close at $4.87 per share on August 17, 2026. Then, on October 19, 2026, EyePoint announced disappointing topline results from its second Phase 3 pivotal clinical trial, LUCIA, evaluating Duravyu for the treatment of wet AMD. The Company disclosed that Duravyu failed to meet its prespecified primary efficacy endpoint of demonstrating statistical non-inferiority in mean change in best corrected visual acuity (BCVA) compared to the standard-of-care control, Regeneron's Eylea (aflibercept). In response to the clinical failure, EyePoint announced significant cost-cutting measures, including the immediate termination of its late-stage wet AMD clinical program and a 53% workforce reduction designed to restructure its operations around separate diabetic macular edema programs. Following this news, EyePoint's stock price fell $2.55 per share, or 85.28%, to close at $0.44 per share on October 19, 2026.

What's Next for EyePoint Investors?

If you are aware of any facts relating to this investigation or purchased EyePoint securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/eyepoint-inc-eypt-investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to EyePoint Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for EyePoint Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC